New Delhi, September 6: Drug Controller General of India (DCGI) Rajeev Singh Raghuvanshi has issued an advisory to discontinue the use of antacid Digene Gel manufactured by drugmaker Abbott India at its Goa unit. The DCGI has issued the advisory following a compliant on August 9 alleging that one bottle of Digene Gel mint flavour is of regular taste (sweet) and light pink colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour. Congress Leader Shashi Tharoor Suggests ‘BHARAT’ Name for Opposition Bloc Amid India-Bharat Row

The DCGI said the  impugned product manufactured at the Goa facility may be unsafe and its use may result in adverse reaction. "The doctors and healthcare professionals should carefully prescribe and educate their patients to discontinue the use and for reporting of any ADRs (adverse drug reactions ) arising due to consumption of the said product. Healthcare professionals should promptly report any suspicious cases of adverse events linked to this product," read the advisory issued by Dr Raghuvanshi recently. Vivo V29 5G Launch Likely on September 7: Know Expected Specifications, Camera, Battery and Other Details

It further said the said product within active shelf life to be removed from the distribution. The DCGI also asked States/Union Territories Drugs Controllers to keep strict vigil on the movement, sale, distribution, stock of the drug products in the market, draw samples if the product lying in market and initiate necessary action as per the provisions of the Drugs and Cosmetics Act and Rules. Abbott India in its letter to DCGI on August 11 said it had voluntarily recalled the impugned product and also stopped production of all variants of Digene Gel manufactured at their Goa facility, as per the regulator.

(The above story first appeared on LatestLY on Sep 06, 2023 03:53 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).